Systemic cytotoxic and biologic therapies for colorectal cancer liver metastases: Expert consensus statement

HPB

Volumn 15, Issue 2, 2013, Pages 116-118

  Clary, Bryan M ^a   Grothey, Axel ^b   Kopetz, Scott ^c   Marsh, Robert D W ^d  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; REGORAFENIB;

CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURGERY; CHEMOEMBOLIZATION; COLORECTAL CANCER LIVER METASTASIS; HUMAN; LIVER FUNCTION; LIVER HISTOLOGY; LIVER METASTASIS; LIVER RESECTION; NOTE; RADIOFREQUENCY ABLATION; TREATMENT DURATION;

EID: 84872182798     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/j.1477-2574.2012.00598.x     Document Type: Note

References (13)

1. Schwarz RE, Berlin JD, Lenz HJ, Nordlinger B, Rubbia-Brandt L, Choti MA,. (2013) Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statement. HPB 15: 106-115.
2. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier PB, et al. (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): A randomized controlled trial. Lancet 371: 1007-1016. (Pubitemid 351392040)
3. Saltz LB, Niedzwiecki D, Hollis D, Goldberg RM, Hantel A, Thomas JP, et al. (2007) Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol 25: 3456-3461. (Pubitemid 47310883)
4. Ychou M, Hohenberger W, Thezenas S, Navarro M, Maurel J, Bokemeyer C, et al. (2009) A randomized phase III study comparing adjuvant 5-fluorouracil/ folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol 20: 1964-1970.
5. Rubbia-Brandt L, Lauwers GY, Wang H, Majno PE, Tanabe K, Zhu AX, et al. (2010) Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology 56: 430-439.
6. Kishi Y, Zorzi D, Contreras CM, Maru DM, Kopetz S, Ribero D, et al. (2010) Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol 17: 2870-2876.
7. Van Cutsem E, Bokemeyer C, Heeger S, Sartorius U, Rougier P, Kohne C,. (2011) Outcome according to metastatic site in patients with KRAS wild-type tumours: Analysis from the CRYSTAL and OPUS studies. J Clin Oncol 29 (4 Suppl): 472.
8. Arnold D, Andre T, Bennouna J, Sastre J, Osterlund P, Greil R, et al. (2012) Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: results of a randomized phase III intergroup study (TML study). J Clin Oncol 30 (18 Suppl): 3503.
9. Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, et al. (2009) A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 27: 672-680.
10. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, et al. (2009) Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360: 563-572.
11. Zhang C, Wang J, Gu H, Zhu D, Li Y, Zhu P, et al. (2012) Capecitabine plus oxaliplatin compared with 5-fluorouracil plus oxaliplatin in metastatic colorectal cancer: meta-analysis of randomized controlled trials. Oncol Lett 3: 831-838.
12. Grothey A, Sobrero A, Siena S, Falcone A, Ychou M, Lenz H, et al. (2012) Results of a phase III randomized, double-blind, placebo-controlled, multicentre trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies. J Clin Oncol 30 (4 Suppl): LBA385.
13. Joulain F, Van Cutsem E, Iqbal S, Hoyle M, Allegra C,. (2012) Aflibercept versus placebo in combination with FOLFIRI in previously treated metastatic colorectal cancer (mCRC): mean overall survival (OS) estimation from a phase III trial (VELOUR). J Clin Oncol 30 (15 Suppl): 3602.